Optimal Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease

Introduction to PPI Therapy

The American Gastroenterological Association recommends that selection of a PPI should be based primarily on cost and availability, as all PPIs are highly effective for treating typical GERD in adults with no single agent demonstrably superior in terms of clinical outcomes 1

PPIs as a drug class are more effective than H2-receptor antagonists, which are more effective than placebo, for healing esophagitis and providing symptomatic relief in GERD 1
Standard once-daily PPI dosing should be the initial approach, taken 30-60 minutes before the first meal of the day for optimal acid suppression 2
The American College of Gastroenterology suggests that the timing is critical—PPIs must be taken before meals to coincide with the postprandial peak in active proton pumps for maximum efficacy 2

If standard once-daily dosing fails to control symptoms adequately, escalate to twice-daily dosing before switching agents, as recommended by the American Gastroenterological Association 1
Almost all efficacy data comes from once-daily dosing studies, but expert consensus unanimously recommends twice-daily dosing for patients with unsatisfactory response to once-daily therapy 1
However, avoid twice-daily dosing as initial therapy—it lacks FDA approval for this indication and strong evidence support while unnecessarily increasing costs, according to the American College of Gastroenterology 2

Initial treatment should continue for 4-8 weeks for healing of erosive lesions, as suggested by the American College of Gastroenterology 2
For patients with documented erosive esophagitis, continuous daily PPI therapy is required indefinitely to prevent recurrence—on-demand or intermittent therapy is explicitly contraindicated, according to the American Gastroenterological Association 2

Never use on-demand or intermittent PPI therapy for patients with documented erosive esophagitis—this approach is only appropriate for non-erosive reflux disease and leads to high recurrence rates, as recommended by the American College of Gastroenterology 2
Do not substitute H2-receptor antagonists for maintenance therapy in erosive disease—they are significantly less effective, with patients up to twice as likely to have recurrent disease, according to the American College of Gastroenterology 2
Do not add a nocturnal H2RA to twice-daily PPI therapy—there is no evidence of improved efficacy with this combination, as stated by the American Gastroenterological Association 1
The American Thoracic Society recommends that in patients with unexplained chronic cough and a negative workup for acid reflux disease, PPI therapy should not be prescribed 3

The American College of Physicians guidelines suggest that repeat endoscopy is justified in patients with erosive gastritis who have persistent symptoms despite adequate proton pump inhibitor (PPI) therapy, to investigate for treatment failure, complications, or alternative diagnoses 4, 5, 6
Patients with severe erosive esophagitis (Los Angeles grade C or D) require follow-up endoscopy after 8 weeks of PPI therapy to assess healing and rule out Barrett's esophagus, as approximately 6% may have underlying Barrett's esophagus unmasked after healing 5
Repeat endoscopy is indicated if symptoms persist despite 4-8 weeks of twice-daily PPI therapy, representing treatment failure requiring investigation 4, 6, 7
Alarm symptoms such as dysphagia, bleeding, anemia, weight loss, or recurrent vomiting warrant immediate endoscopy 4, 8

Before proceeding with repeat endoscopy, patients should have completed 4 to 8 weeks of twice-daily PPI therapy taken 30-60 minutes before meals 4, 5
Any PPI agent is acceptable (e.g. omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, or dexlansoprazole) as efficacy differences are minimal 5

Do not repeat endoscopy if the patient has not completed an adequate trial of twice-daily PPI therapy for 4-8 weeks 4, 5
Do not assume that 6 months of persistent symptoms automatically warrants endoscopy without first optimizing medical therapy 4, 5
Recurrent endoscopy after a normal follow-up examination is not indicated in the absence of Barrett's esophagus or new symptoms 4, 7